https://www.selleckchem.com/products/Nolvadex.html
13, P = 0.02), duration of dyslipidemia (B = -0.22, P 0.01), receiving high-intensity statin (B = -0.18, P 0.01) or statin in combination with fibrate (B = -0.15, P 0.01) were associated with lower HRQOL. HRQOL has considerable scope for improvement in patients with dyslipidemia in Jordan. Improving dyslipidemia medications' beliefs and simplifying medication regimen by prescribing less medications, particularly for patients with longer disease duration and those on statin therapy, should be considered in future manageme
Curtir
Comentario
Compartilhar
